Pharmacological and biotechnological advances with Rosmarinus officinalis L

ABSTRACT

Introduction: Rosmarinus officinalis L. is an aromatic plant with a number of biological properties. Recently, has been studied regarding its therapeutic potential. The objective of this study was to perform a systematic review on R. officinalis essential oil for its pharmacological properties and biotechnological applications.

Areas covered: The databases were searched for articles (Science Direct, Pub Med and Web of Science) and patents (INPI, WIPO and EPO) with publications on R. officinalis and associations with essential oil (EO-Ro), cardiovascular system, hypertension and cyclodextrin. We selected 305 articles on EO-Ro in the most diverse subjects and six articles with of R. officinalis associated with hypertension. 59 patents were analyzed. The results demonstrate how extensive the studies are on the biological activities with the extract and EO-Ro. These have shown effects antibacterial, antifungal, anti-inflammatory, antitumor and other. The properties exhibited by EO-Ro reinforce the use of this plant as a phytotherapeutic agent.

Expert opinion: Although there are several pharmacological properties, studies on the prevention or treatment of cardiovascular diseases with EO-Ro are scarce, especially to evaluate the antihypertensive activity of EO-Ro. It has also become clear that EO-Ro can be exploited in different commercial products as supplement, cosmetics and new formulations

KEYWORDS:

• Antihypertensive
• biotechnology
• essential oil
• natural product
• rosemary

Article highlights

• This review covers patents on therapeutic (pharmacological) activities, advances over R. officinalis evidencing in the last 11 years (2006–2017).

• Pharmacological results showed that the essential oil of R. officinalis has great potential in the inflammation treatment, hypertension, and diabetes.

• This therapeutic patents literature review did not demonstrate the use of cyclodextrin (CD).

• This review provides a literature overview on non-therapeutic patents in this period (2006–2017).

This box summarizes key points contained in the article.

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Supplementary material

Supplemental data for this article can be accessed here.

Additional information

Funding

This paper was not funded.